Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 5, 2008, Pages 903-910

  Bartsch, Rupert ^a   Wenzel, Catharina ^a   Gampenrieder, Simon P ^a   Pluschnig, Ursula ^a   Altorjai, Gabriela ^a   Rudas, Margaretha ^a   Mader, Robert M ^a   Dubsky, Peter ^a   Rottenfusser, Andrea ^a   Gnant, Michael ^a   Zielinski, Christoph C ^a   Steger, Guenther G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Advanced breast cancer; Gemcitabine; Her2 positive disease; Palliative chemotherapy; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; DOCETAXEL; GEMCITABINE; NAVELBINE; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BRAIN METASTASIS; BREAST CARCINOMA; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; MONOTHERAPY; MYALGIA; NAUSEA; NEUTROPENIA; ONCOGENE NEU; PRIORITY JOURNAL; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 49749094419     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0682-1     Document Type: Article

References (44)

1. WF Anderson AS Reiner RK Matsuno 2007 Shifting breast cancer trends in the United States J Clin Oncol 25 3923 3929
2. World Health Organization Facts and Figures (2007) http://www.who.int. Cited 1 August 2007
3. American Cancer Society Facts and Figures (2005) http://www.cancer.org. Cited 1 August 2007
4. EH Romond EA Perez J Bryant 2005 Trastuzumab plus adjuvant chemotherapy for operable Her2-positive breast cancer N Engl J Med 353 1673 1684
5. IF Faneyte JL H Van Peterse Tinteren 2004 Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement Clin Cancer Res 10 4457 4463
6. Slamon DJ, Clark GM, Wong SG et al Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science (Washington DC) 235:177-182
7. JS Boss JA Fletcher GP Linette 2003 The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy Oncologist 8 307 325
8. S Paik R Hazan ER Fisher 1990 Pathologic finding from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein expression in primary breast cancer J Clin Oncol 8 103 112
9. OP Kallioniemi K Holli T Visakorpi 1991 Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer Int J Cancer 4 650 655
10. RA Clynes TL Towers LG Presta 2006 Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets Nat Med 6 443 446
11. R Nahta D Yu MC Hung 2006 Mechanisms of disease: understanding resistance to Her2-targeted therapy in human breast cancer Nat Clin Pract Oncol 3 269 280
12. M Harris I Smith 2002 The development and clinical use of trastuzumab (Herceptin) Endocr Related Cancer 9 75 85
13. DJ Slamon B Leyland-Jones S Shak 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792
14. Amar S, Moreno-Aspitia A, Perez EA (2007) Issues and controversies in the treatment of HER2 positive metastatic breast cancer. Breast Cancer Res Treat [Epub ahead of print]
15. CE Geyer J Forster D Lindquist 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733 2743
16. Fountzilas G, Razis E, Tsavdaridis D et al (2003) Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic cooperative oncology group. Clin Breast Cancer 120-125
17. D Tripathy D Slamon M Cobleigh 2004 Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression J Clin Oncol 6 1063 1070
18. R Bartsch C Wenzel D Hussian 2006 Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study BMC Cancer 6 63
19. R Bartsch C Wenzel G Altorjai 2007 Capecitabine and trastuzumab in heavily pretreated patients with metastatic breast cancer J Clin Oncol 25 3853 3858
20. M Pegram S Hsu G Lewis 1999 Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers Oncogene 18 2241 2251
21. G Schaller I Fuchs T Gonsch 2007 Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes J Clin Oncol 25 3246 3250
22. CJA Van Moorsel GJ Peters HM Pinedo 1997 Gemcitabine: future prospects of single-agent and combination studies Oncologist 2 127 134
23. JF Bishop JP Matthews GA Young 1996 A randomized study of high-dose cytarabine in induction therapy in acute myeloid leukaemia Blood 5 1710 1717
24. SB Kaye 1994 Gemcitabine: Current status of phase I and II trials J Clin Oncol 12 1527 1531
25. V Heinemann LW Hertel GB Grindey 1988 Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-d-arabinofuranosylcytosine Cancer Res 48 4024 4031
26. J Carmichael K Possinger P Phillip 1995 Advanced breast cancer: a phase II trial with gemcitabine J Clin Oncol 13 2731 2736
27. T Brodowicz WJ Kostler R Moslinger 2000 Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer Breast 9 228 342
28. M Blackstein CL Vogel R Ambinder 2002 Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial Oncology 62 2 8
29. Chan S, Romieu G, Huober J et al (2005) Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel for anthrcycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. In: Presented at the 41st ASCO annual meeting, Orlando, Fl, 13-17 May 2005. http://www.asco.org. Cited 30 August 2007
30. C Zielinski S Beslija Z Mrsic-Krmpotic 2005 Gemcitabine, epirubicine and paclitaxel versus fluorouracil, epirubicine and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group international multicenter, prospective, randomized phase III trial J Clin Oncol 23 1401 1408
31. JA O'Shaughnessy R Pluenneke J Sternberg 2006 Phase II trial of weekly docetaxel/gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer Clin Breast Cancer 6 505 510
32. J O'Shaughnessy D Miles S Vukelja 2002 Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results J Clin Oncol 20 2812 2823
33. B Leyland-Jones K Gelmon JP Ayoub 2003 Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel J Clin Oncol 21 3965 3971
34. CH Smorenburg M Bontebal C Seynaeve 2001 Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane Breast Cancer Res Treat 66 83 87
35. MD Pegram GE Konecny C O'Callaghan 2004 Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer J Natl Cancer Inst 96 739 749
36. JA ÓShaughnessy S Vukelja T Marsland 2004 Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer Clin Breast Cancer 5 142 147
37. HJ Burstein LN Harris PK Marcom 2003 Trastuzumab and Vinorelbine as first-line therapy forHer2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm J Clin Oncol 21 2889 2895
38. Dent S, Messersmith H, Trudeau M (2007) Gemcitabine in the management of metastatic breast cancer: a systematic review. Breast Cancer Res Treat [Epub ahead of print]
39. JC Bendell SM Domchek HJ Burstein 2003 Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma Cancer 97 2972 2977
40. E Shmueli N Wigler M Inbar 2004 Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment Eur J Cancer 40 379 382
41. AJ Clayton S Danson S Jolly 2004 Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer Br J Cancer 91 639 643
42. EE Lower DR Drosick R Blau 2003 Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival Clin Breast Cancer 4 114 119
43. DG Kirsch CJ Ledezma CS Mathews 2005 Survival after brain metastases from breast cancer in the trastuzumab era J Clin Oncol 39 2114 2116
44. Bartsch R, Rottenfusser A, Wenzel C et al (2007b) Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol [Epub ahead of print]